GSK4027

Target: GSK4027 targets the bromodomains of PCAF/KAT2B and GCN5/KAT2A as a chemical probe.

Mechanism of Action: GSK4027 can be applied as an acetyl-lysine reader ligand for PROTACs intended to engage PCAF or GCN5 bromodomains. The GSK4027-derived module supplies target recognition, while a chemically compatible linker connects it to an E3 ligase ligand. The resulting degrader is evaluated for simultaneous bromodomain and E3 engagement, because degradation requires a ternary complex with favorable orientation and stability. If ternary-complex geometry supports ubiquitin transfer, PCAF or GCN5 is polyubiquitinated and degraded by the proteasome instead of only being occupancy-inhibited. This establishes a testable protein-depletion mechanism for research assays.

• PROTAC-Based BRD4 Degradation: GSK4027 can be used as a ligand component to construct PROTACs aimed at inducing ubiquitin-mediated degradation of BRD4. By enabling productive ternary complex formation with BRD4 and an E3 ligase, PROTACs can reduce BRD4 protein levels, offering a mechanistic tool to probe BRD4-dependent transcriptional programs.

• Ternary Complex Optimization: Incorporating GSK4027 into PROTAC designs supports systematic optimization of linker length, composition, and attachment geometry to enhance ternary complex stability. Improved cooperative binding can increase ubiquitination efficiency and degradation potency, enabling researchers to map structure–activity relationships that govern target engagement versus catalytic degradation.

• E3 Ligase Recruitment Studies: PROTACs built with GSK4027 can be paired with diverse E3 ligase recruiters to evaluate how ligase selection influences BRD4 degradation kinetics. This application supports comparative studies of ubiquitin pathway engagement, helping identify conditions that maximize degradation while minimizing off-target effects through ligand–ligase compatibility.

• Mechanistic Pathway Dissection: Using GSK4027-based PROTACs allows investigation of degradation mechanisms, including dependence on the proteasome and ubiquitin conjugation. Researchers can employ pathway perturbations to determine whether BRD4 loss follows canonical ubiquitin–proteasome routing, and to quantify degradation versus inhibition of BRD4 function.

• Transcriptional Consequence Profiling: GSK4027-derived PROTACs can be used to study downstream transcriptional outcomes of BRD4 degradation. By correlating protein depletion with changes in BRD4-regulated gene expression and chromatin-associated processes, researchers can distinguish degradation-driven effects from occupancy-only pharmacology, refining target validation strategies.

GSK4027 is a PCAF/GCN5 bromodomain chemical probe that provides a non-kinase target-ligand scaffold for degrader design. Its brominated pyridazinone core and chiral piperidinyl amino substituent support structure-enabled studies of acetyl-lysine reader protein degradation. This molecule is described in detail below.

Structure: The structure contains a bromo-methyl pyridazinone linked to a chiral N-methyl phenylpiperidine through an amino substituent. The heteroaryl lactam-like core, aryl group, and tertiary amine create a balanced recognition element with defined stereochemistry.

Reactivity: For PCAF/GCN5 degrader development, linker introduction should avoid the bromopyridazinone and chiral amino recognition elements unless structural data confirm solvent exposure; peripheral piperidine or aryl substituent analogues may be more appropriate for exit-vector scanning. Alkyl, PEG, or mixed polarity linkers can be connected to CRBN or VHL ligands, while alternative E3 recruiters may be explored to optimize bromodomain ternary-complex geometry.